Top Tweets for #Mtap
OMG KIT IS DOING A STREAM!? (Thank goodness!) #MTAP #MyTimeAtPortia #letsplay #live --> https://t.co/cZKted424S
🧬Exciting early clinical signal in #MTAP-deleted, #KRAS-mutant #PDAC:
#Vopimetostat (PRMT5 inhibitor) + #daraxonrasib (RAS(ON) inhibitor) showed strong early Phase 1/2 activity in metastatic pancreatic cancer: 92% ORR (11/12 patients)
Early days, but promising for a historically hard-to-treat cancer type.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/ihm5Y5mXoc
Daraxonrasib 👉 https://t.co/ub6RdmJODU
🧬Molecule of the Moment | #vopimetostat + #daraxonrasib
@TangoTxOncology reported encouraging early Phase 1/2 data for vopimetostat (#PRMT5 inhibitor) in combination with Revolution Medicines’ RAS(ON) inhibitor in #MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (#PDAC).
📊Key signals:
• 92% ORR (11/12 patients)
• 100% DCR
• ~90% 6-month PFS
In a tumor type long defined by therapeutic resistance, these results suggest true combination synergy rather than incremental benefit. Mechanistic rationale is converging:
• #RAS(ON) inhibition → dampens oncogenic signaling
• PRMT5 inhibition (MTAP-del context) → exploits synthetic lethality/metabolic vulnerability
• Together → collapse of both signaling + survival buffering
⚠️Still early: small cohorts, with key questions remaining around durability, resistance, and tolerability.
The outcome goes beyond tumor shrinkage—hinting at early durability signals driven by combination biology. If validated, MTAP-del + KRAS-mutant PDAC may become a case where tumor genotype defines a combination backbone, not just drug eligibility.
Overall, the broader direction is becoming clearer: from single-node targeting → to coordinated pathway suppression in genomically defined tumors.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/hYnMVMe3aP
Daraxonrasib 👉 https://t.co/or24dj5iUH
#KRAS #PrecisionOncology #PancreaticCancer
🧬Molecule of the Moment | #vopimetostat + #daraxonrasib
@TangoTxOncology reported encouraging early Phase 1/2 data for vopimetostat (#PRMT5 inhibitor) in combination with Revolution Medicines’ RAS(ON) inhibitor in #MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (#PDAC).
📊Key signals:
• 92% ORR (11/12 patients)
• 100% DCR
• ~90% 6-month PFS
In a tumor type long defined by therapeutic resistance, these results suggest true combination synergy rather than incremental benefit. Mechanistic rationale is converging:
• #RAS(ON) inhibition → dampens oncogenic signaling
• PRMT5 inhibition (MTAP-del context) → exploits synthetic lethality/metabolic vulnerability
• Together → collapse of both signaling + survival buffering
⚠️Still early: small cohorts, with key questions remaining around durability, resistance, and tolerability.
The outcome goes beyond tumor shrinkage—hinting at early durability signals driven by combination biology. If validated, MTAP-del + KRAS-mutant PDAC may become a case where tumor genotype defines a combination backbone, not just drug eligibility.
Overall, the broader direction is becoming clearer: from single-node targeting → to coordinated pathway suppression in genomically defined tumors.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/hYnMVMe3aP
Daraxonrasib 👉 https://t.co/or24dj5iUH
#KRAS #PrecisionOncology #PancreaticCancer
Want to know more about how KRAS & MTAP 🧬 alterations converge in PDAC including tumor microenvironment features? You can check now at @CCR_AACR! @UTMDAnderson @AhnertJord67866 @DavidHongMD @DanZhaoMD @DrShubhamPant @BostonGeneCorp #pancreaticcancer #KRAS #MTAP
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications | Clinical Cancer Research | American Association for Cancer Research https://t.co/8um8IN7ksn
Wishing a very, very happy birthday my friend and colleague, the #RET and #MTAP oncology 👑, @mihaela_aldea ! ❤️❤️❤️
May your birthday be filled with joy, love, and learning! @ASCO @IASLC #ASCO26 #LCSM #LCAM @RETpositive @TurgemanIlit
#ASCO2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #HER2 #RAS #BTC! Advanced Fellow Aruj Dhyani #YIA #ADC #BTC Assistant Attending @rohit_thum #MTAP #NET #BTC #PDAC. Glad to mentor, but grateful for what you teach me too!
#ASCO26 poster session with @rohit_thum, who shares his research about “Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers" with a fellow attendee. @ASCO
Insert catchy surprise stream info here!? #MTAP #live #MyTimeAtPortia --> https://t.co/9IoZGRYfu4
🔜 #ELCC26 @myESMO 🇩🇰
🔥New horizons in therapeutic targets for thoracic malignancies
☑️ #SMARCA4 #MTAP #Bispecific #Trispecific #ADC
🎙️Chair: Dr. Keith M. Kerr @JunTanizaki3
@OncoAlert @Larvol #LCSM
Risk my life for 500, Alex! #MTAP #MyTimeAtPortia #letsplay w/my @TigerLover78 --> https://t.co/oOUqBlbBIA
With the development of novel #MTAcooperative #PRMT5inhibitors, #MTAP deficiency has become an important #target to be exploited through #SyntheticLethality.
Had the opportunity to discuss this at an #educationalsession dedicated to Rare Thoracic Cancers during @myESMO #ESMORareCancers26. Happy to share some key slides and takeaways.
#drugdevelopment @CUHKMedicine #CUHKSarcoma @apoddc @APCLC_2023
Better late than never (grandma) we're a GO with #MTAP #MyTimeAtPortia #live --> https://t.co/FUss5VvYMt
Last Seen Hashtags on Sotwe
hidayaturrehmanbaloch
Seen from United States
omegle
Seen from Turkey
NMatATS
Seen from United States
RIWOOnderful_Day
Seen from United States
beylikduzutravesti
Seen from Turkey
bursatravesti
Seen from Turkey
momsonn
Seen from Japan
momson((()))*+filter:native_video
Seen from Netherlands
momsonn()**** filter:videos since:2026-08-03
Seen from Singapore
la男娘
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.6M followers
Taylor Swift
@taylorswift13
83.5M followers
Lady Gaga
@ladygaga
75M followers
Virat Kohli
@imvkohli
72.8M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.7M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.7M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers